Abstract
Abstract Study question What are the medical and ethical challenges of performing ovarian stimulation and oocyte cryopreservation in adolescents and what are the barriers to provision? Summary answer Oocyte cryopreservation for benign and malignant indications in adolescents is associated with unique medical and ethical challenges. What is known already An improvement in childhood cancer survival, increased transgender care and benign conditions such as haemoglobinopathies requiring stem cell transplant have led to higher representation of adolescent birth-registered females in FP clinics. FP in adolescents has increased complexities, both physical (pubertal stage, diagnosis) and psychological (accepting diagnosis, processing information, decision-making). Concerns relate to reliability of AMH in adolescents, anticipated response to ovarian stimulation and oocyte quality. Counselling and consenting young people and their families about fertility decisions, often alongside receiving a life-changing diagnosis, is an ethically complex area. Assessing capacity to consent is not straightforward. We report our clinical experience. Study design, size, duration This was a retrospective, observational cohort study of 26 adolescent birth-registered females aged 13 to 18 years who underwent ovarian stimulation and oocyte cryopreservation in a specialist unit for fertility preservation between 2018 and 2022. The primary outcome was oocyte yield, secondary outcomes included complications and drop-out rate. Participants/materials, setting, methods We included post-pubertal adolescent birth-registered females aged 13 to 18 years who were referred for fertility preservation for high risk of gonadotoxicity from treatment and who commenced ovarian stimulation for oocyte cryopreservation. Data was retrieved from a prospectively managed database. We noted demographic data, ovarian reserve, method of monitoring, response to ovarian stimulation and oocyte cryopreservation and route of egg collection. Documentation on counselling conversations and psychological maturity was retrieved from clinical records. Main results and the role of chance There were a total of 29 ovarian stimulation cycles performed in 26 adolescent birth-registered females aged between 13 and 18 years. Indications for fertility preservation included malignancy 62% (16/26), immunological disorders 19% (5/26), gender reassignment treatment 8% (2/26), recurrent ovarian cyst surgery 8% (2/26) and benign haematological disease 4% (1/26). The youngest was aged 13 years and 10 months at the time of egg collection. Minimum time from menarche to ovarian stimulation was 11 months. 23% (6/26) adolescents had previously received chemotherapy. AMH was 2.8-37 pmol/L and AFC 2-36. AFC correlated well with AMH in the majority. Random-start was performed in 54% (14/26) and dual stimulation in 12% (3/26). Number of cryopreserved oocytes was 3-45 and number of MII oocytes cryopreserved 3-35. Ultrasound monitoring was performed transabdominally in 88% (23/26) and transvaginally in 12% (3/26). Egg collection was performed transvaginally in all cases in this cohort, comprising adolescents from varying ethnicities. All cycles proceeded to completion. There were no complications in any cycle, including the 42% (11/26) performed for haematological malignancy. All adolescents were counselled in association with a family member to obtain informed consent. All were assessed as able to comprehend discussions. Limitations, reasons for caution There is limited data on performing oocyte cryopreservation in adolescents. Further studies expanding on our findings are needed to support clinicians to perform oocyte cryopreservation in this population. Concerns remain regarding increased aneuploidy rates in this age group compared to women in their 20s. Livebirth outcome data is needed. Wider implications of the findings This is the largest case series to date. Post-pubertal adolescents as young as age 13 can undergo ovarian stimulation and oocyte cryopreservation. Transvaginal egg collection is an accepted procedure when counselled appropriately. Clinician experience, correct setting and funding enable a permissive environment for oocyte cryopreservation in this population. Trial registration number N/A
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.